

IN THE CLAIMS:

Amend the claims as follows:

1. (Original) A method for inhibiting KDR/Flk-1 signal transduction, which comprises using a substance which inhibits binding of a signal transduction molecule to 1175-tyrosine phosphorylated KDR/Flk-1.

2. (Original) A method for inhibiting cell growth, which comprises using a substance which inhibits binding of a signal transduction molecule to 1175-tyrosine phosphorylated KDR/Flk-1.

Claims 3-9 (Canceled).

10. (Currently Amended) The method according to any one of claims ~~1 to 9~~to 2, wherein the signal transduction molecule is phospholipase C- γ (PLC- γ).

11. (Currently Amended) The method according to any one of claims ~~1 to 9~~to 2, wherein the substance which inhibits binding of a signal transduction molecule to 1175-tyrosine phosphorylated KDR/Flk-1 is an antibody which specifically recognizes 1175-tyrosine phosphorylated KDR/Flk-1.

12. (Original) The method according to claim 11, wherein the antibody which specifically recognizes 1175-tyrosine phosphorylated KDR/Flk-1 is an antibody which

binds to the 1175-tyrosine phosphorylated KDR/Flk-1 and inhibits phosphorylation of PLC- γ .

13. (Currently Amended) The method according to claim 11 ~~or 12~~, wherein the antibody is a monoclonal antibody or the antibody fragment thereof.

Claims 14-41 (Canceled).

42. (new) The method according to claim 12, wherein the antibody is a monoclonal antibody or the antibody fragment thereof.